Molecular underpinnings of clinical disparity patterns in African American vs. Caucasian American multiple myeloma patients

Dickran Kazandjian, Elizabeth Hill, Malin Hultcrantz, Evan H. Rustad, Venkata Yellapantula, Theresia Akhlaghi, Neha Korde, Sham Mailankody, Alex Dew, Elli Papaemmanuil, Irina Maric, Mary Kwok, Ola Landgren

Research output: Contribution to journalArticlepeer-review

18 Scopus citations

Abstract

Caucasian Americans (CA) compared with African Americans (AA) have a twofold increased incidence of multiple myeloma (MM) and have an earlier age of diagnosis. However, there is sparse information regarding underlying biological differences across racial/ethnic groups. We characterized genetic alterations using a targeted next-generation sequencing assay called myTYPE, developed at MSKCC, allowing capture of somatic mutations, IgH translocations, gains/losses, and hyperdiploidy. Samples were obtained from the NIH Plasma Cell Dyscrasia Racial Disparity Cohort. In total, 68 patient samples were successfully sequenced and manually curated based on well-established databases. Of the 68 patient samples (47 CA, 21 AA), 84% had at least one type of genomic alteration. Importantly, the IgH translocation, t(11;14), was observed more frequently in the AA group (0 vs. 29%, p = 0.001). Known oncogenic somatic non-synonymous mutations were found in 18 genes and indels in 2 genes. KRAS mutations were the most common mutation found in 16% of patients followed by NRAS and BRAF mutations. TP53 somatic mutations appeared to be more common in CA but lacked significance. This proof-of-principle study indicates the presence of varying underlying tumor biology between racial groups and supports the need of future prospective trials to capture these molecular characteristics.

Original languageEnglish (US)
Article number15
JournalBlood cancer journal
Volume9
Issue number2
DOIs
StatePublished - Feb 1 2019
Externally publishedYes

ASJC Scopus subject areas

  • Hematology
  • Oncology

Fingerprint

Dive into the research topics of 'Molecular underpinnings of clinical disparity patterns in African American vs. Caucasian American multiple myeloma patients'. Together they form a unique fingerprint.

Cite this